New drug duo aims to outsmart tough cancers
NCT ID NCT03162627
Summary
This study is testing whether combining two drugs, selumetinib and olaparib, can help control advanced or returning solid tumors. The first phase aims to find the safest, highest dose of the combination. The second phase will see if that dose helps patients with specific cancers, including ovarian and endometrial tumors that have certain genetic changes or have stopped responding to similar drugs. All participants will take the drugs orally as long as they are benefiting.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT NEOPLASM OF BREAST are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.